Agenda

Tuesday, Oct 2 Wednesday, Oct 3

Tuesday, October 2, 2018

08:30 am - 08:35 am EST
Welcome: S. Perwez Hussain, Ph.D.

Chair: Pancreatic Cancer Interest Group, NCI

08:35 am - 08:45 am EST
Opening Remarks: William Dahut, M.D.

Scientific Director for Clinical Research, Center for Cancer Research, NCI

08:45 am - 09:25 am EST
Keynote Lecture: New insights into pancreatic cancer etiology and treatment

David Tuveson, M.D., Ph.D.
Cold Spring Harbor Laboratory, NY

Session 1: Early Detection

Chair: David Tuveson, M.D., Ph.D.

09:25 am - 09:50 am EST
Updates on the early detection of pancreatic cancer

Teresa Brentnall, M.D.
University of Washington School of Medicine, Seattle, WA

09:50 am - 10:15 am EST
Detection of Pancreatic Cancer - Potential Of Circulating Tumour DNA

Anne Marie Lennon M.D., Ph.D
Johns Hopkins School of Medicine, Baltimore, MD

10:15 am - 10:40 am EST
Novel autoantibody signatures in sera of patients with pancreatic cancer, chronic pancreatitis and autoimmune pancreatitis; a protein microarray profiling approach

Klaus Felix, Ph.D. 
DKFZ, Heidelberg, Germany

10:40 am - 10:55 am EST
Break

Session 2: Metabolic Reprogramming

Chair: Thomas Ried, M.D.

 

10:55 am - 11:20 am EST
Metabolic reprogramming in pancreatic cancer

Jordan Winter, M.D. 
University Hospitals Cleveland Medical Center

11:20 am - 11:45 am EST
Metabolic alterations cause chemotherapy resistance in pancreatic cancer

Pankaj Singh, Ph.D. 
University of Nebraska Medical Center, NE

11:45 am - 12:30 pm EST
Lunch on your own

Session 3: Inflammatory/Immune Signaling, Novel therapeutic Targets

Chair: Dianne Simeone, M.D.

12:30 pm - 12:55 pm EST
Nuclear complexes in inflammation-induced pancreatic carcinogenesis

Volker Ellenrieder, M.D., Ph.D. 
University Medical Center, Gottingen, Germany

12:55 pm - 01:20 pm EST
Changes in the histological growth pattern of pancreatic cancer - a matter of the immune infiltrate

Matthias Gaida, M.D. 
Institute of Pathology, University of Heidelberg, Germany

01:20 pm - 01:45 pm EST
STAT3/Survivin axis: a potential therapeutic target

Pratap Kumar, Ph.D. 
University of Texas, San Antonio, TX

01:45 pm - 02:10 pm EST
Regulatory pathways of metastasis and immunosuppression in pancreatic cancer

Wei Zhang, Ph.D.
Wake Forest Baptist Comprehensive Cancer Center, NC

02:10 pm - 02:35 pm EST
Beyond apoptosis, Bcl-xL in pancreatic neuroendocrine tumor metastasis

Yi-Chieh Nancy Du, Ph.D.
Weill Cornell Medicine, NY

02:35 pm - 03:20 pm EST
Poster Presentation

Session 3 (Continued)

Chair: Volker Ellenrieder, M.D.

03:20 pm - 03:45 pm EST
An alternative approach to targeting pancreatic cancer

Jonathan Brody, Ph.D
Thomas Jefferson University, PA

03:45 pm - 04:10 pm EST
Novel target-specific nanoparticles decrease growth of pancreatic cancer and block metastases

Jill Smith, M.D.
Georgetown School of Medicine, Washington, DC

04:10 pm - 04:35 pm EST
IL-6 signaling pathway in pancreatic cancer

Jiayuh Lin, Ph.D.
University of Maryland Sch. of Medicine, MD

04:35 pm - 05:00 pm EST
Inflammatory mediators as potential therapeutic targets

S. Perwez Hussain, Ph.D.
Center for Cancer Research, NCI

Wednesday, October 3, 2018

08:30 am - 09:10 am EST
Keynote Lecture: On the move: How pancreatic cancer cells modulate the epithelial program to invade and metastasize

Benjamin Stanger, M.D., Ph.D.
University of Pennsylvania School of Medicine, PA

Session 4: Treatment and Clinical Advances

Chair: Raffit Hassan, M.D.

09:10 am - 09:35 am EST
Borderline resectablity in pancreatic cancer – an indication for neoadjuvant therapy

Thilo Hackert, M.D.
Heidelberg University Hospital, Heidelberg, Germany

09:35 am - 10:00 am EST
Histopathological aspects in pancreatic head resection: A surgeon’s view

Jochen Gaedcke, M.D.
University of Medicine, Gottingen, Germany

10:00 am - 10:25 am EST
A novel approach for pancreatic cancer treatment

Zhi-Ren Liu, M.D.
Georgia State University, GA

10:25 am - 10:40 am EST
Break

Session (Continued)

Chair: Philipp Strobel, M.D.

10:40 am - 11:05 am EST
Using mesothelin-targeted immunotoxins to treat pancreatic adenocarcinoma

Christine Alewine, M.D., Ph.D.
Center for Cancer Research, NCI

11:05 am - 11:30 am EST
Rare pancreatic tumors

Frank Bergmann, M.D.
Darmstadt Hospital, Germany

11:30 am - 11:55 am EST
Cystic Neoplasms of the Pancreas: Path moving forward

Nader Hanna, M.D.
University of Maryland School of Medicine, MD

11:55 am - 12:45 pm EST
Lunch

Session 5: Tumor Biology, Progression and Therapeutic Resistance

Chair: Benjamin Stanger, M.D., Ph.D.

12:45 pm - 01:10 pm EST
Lumican, collagen and the biophysical properties of pancreatic cancer

Jason Fleming, M.D.
Moffitt Cancer Center, Tampa, FL

01:10 pm - 01:35 pm EST
ATDC and NRF2 antioxidant pathways synergized to drive pancreatic initiation and progression

Dianne Simeone, M.D.
New York University Langone Medical Center, NY

01:35 pm - 02:00 pm EST
Nutritional deprivation and intrinsic therapeutic resistance

Keping Xie, M.D., Ph.D. 
MD Anderson Cancer Center, TX

02:00 pm - 02:25 pm EST
Novel functions for APOBEC3A in pancreatic cancer: Beyond deamination

Andrew Rhim, M.D.
MD Anderson Cancer Center, TX

02:25 pm - 02:50 pm EST
A Novel Model of Resectable Pancreatic Cancer for Study of Metastasis and Dormancy

Darren Carpizo, M.D., Ph.D.
RUTGERS Robert Wood-Johnson University Medical School

02:50 pm - 03:15 pm EST
A chromatin basis for lineage, and disease risk in the human pancreas

Efsun Arda, Ph.D.
Center for Cancer Research, NCI

03:15 pm - 03:40 pm EST
The tumor suppressive impacts of the wild-type KRAS allele on pancreatic cancer

Gloria Su, Ph.D.
Columbia University Medical Center, NY

Session 6: Epidemiology

Chair: Laufey Amundadottir, Ph.D.

03:40 pm - 04:05 pm EST
Identification of individuals at high-risk of pancreatic cancer

Alison Klein, Ph.D
Johns Hopkins School of Medicine, Baltimore, MD

04:05 pm - 04:30 pm EST
Pancreatic cancer incidence and survival trends over the past four decades

Rachael Stolzenberg, Ph.D.
Division of Epidemiology and Genetics, NCI

04:30 pm - 04:55 pm EST
Investigating inherited pancreatic cancer risk loci using high throughput genomic approaches

Laufey Amundadottir, Ph.D.
Division of Epidemiology and Genetics, NCI

04:55 pm - 05:00 pm EST
Concluding Remarks